Friday

25th May 2018

EU drugs regulator accused of being too cozy with Big Pharma

  • The parliament has slammed the EU drugs regulator for cozying up to Big Pharma (Photo: www.freeimages.co.uk)

The European Parliament has refused to sign off on the accounts of the EU agency responsible for making sure all medicines in Europe are safe and effective for its citizens to use, accusing the body of being too close to Big Pharma.

The European Medicines Agency's reputation was further bludgeoned on Tuesday when the parliament ordered a special investigation of the regulator over its funding sources, which overwhelmingly come from the pharmaceutical industry and its hiring practices.

Dear EUobserver reader

Subscribe now for unrestricted access to EUobserver.

Sign up for 30 days' free trial, no obligation. Full subscription only 15 € / month or 150 € / year.

  1. Unlimited access on desktop and mobile
  2. All premium articles, analysis, commentary and investigations
  3. EUobserver archives

EUobserver is the only independent news media covering EU affairs in Brussels and all 28 member states.

♡ We value your support.

If you already have an account click here to login.

Completing the bad news for the agency whose claims of objectivity now lie in tatters were accusations from doctors from the Nordic Cochrane Centre, an independent Denmark-based network that publishes systematic reviews of drug efficacy, that the EMA withholds drug trial evidence due for fear of hurting the profits of drug companies.

On Tuesday, a crushing majority of MEPs in a 637-to-four vote refused to sign off on the accounts of the EMA.

There is "no proper guarantee of the independence of experts hired to carry out scientific evaluations of human medicines and some experts had conflicting interests," according to a statement issued by the chamber that described its concerns about the agency as "grave".

A report backed by the deputies that deploys the term "unacceptable" no fewer than five times and describes its concerns as "grave", describes how at the agency, "there is no guarantee that the evaluation of human medicines is performed by independent experts."

According to the MEPs, the alarm is being raised as a result of both hiring practices that do not pay attention to potential staff and expert conflicts of interest and the source of the bulk of the agency's funding, the pharmaceutical industry itself.

The report goes on to warn of "potential risks to the independence of experts/staff involved in the evaluation of medicinal products, which could have not only detrimental consequences to the agency's reputation should the evaluation of products be formally questioned, but also might have negative effects on public health."

The report mentions the case of the EMA's former executive director, Thomas Lonngren, who in December last year, resigned his post announcing that the next month, he was to take up another job for a private consultancy advising the pharmaceutical industry on the development of new medicines and reducing how long it takes to bring a product to market.

The MEPs' report "stresses that this move casts some doubt on the actual independence of the agency."

Within days of Lonngren's announcement, the EMA management board gave this case of ‘revolving doors' a green light, declaring that there was no conflict of interest and wishing him "all success in your future endeavours".

The parliament argued that the board was within its rights to forbid this type of employment, but did not and has demanded that the EMA deliver a list of all comparable cases that have occurred since the creation of the agency and "explain thoroughly the management board's decision in each case."

The case of the slimming pill

The MEPs in particular highlighted the case of the "very late withdrawal from the market" of a so-called slimming pill, benflourex, which was sold under the brand name ‘Mediator', and also demanded "a full and extensive report" from the agency explaining why it took 10 years from the date when the first warning of possible dangerous side effects of this drug was communicated to the agency, before the final decision was taken to withdraw the drug in 2009.

The EMA may yet get into more hot water over this case, as the chamber has asked the agency to detail how any experts and staff involved with the Mediator case were screened for their independence and verified that there was no conflict of interest.

The same day as the vote, the British Medical Journal published an article by two Danish doctors, Peter Gøtzsche and Anders Jørgensen, of the Nordic Cochrane Centre, detailing their struggle to get the EMA to release the results of clinical trials performed on another pair of slimming pills the agency had given the all-clear to.

The one drug, rimonabant from Sanofi-Aventis, traded under brand names such as Slimona and Monaslim until it was taken off the market last year as a result of side effects, notably severe depression and suicidal thoughts. The second, orlistat, is marketed as a prescription under the name Xenical, from Roche, or over the counter as Alli, from GlaxoSmithKline. Public Citizen, a consumer advocacy group has criticised the weight-loss drug's approval questioning its efficacy and raising concerns about side-effects including precancerous lesions of the colon.

"The effect on weight loss in the published trials is small, and the harms are substantial," the doctors wrote in their article. "People have died from cardiac and pulmonary complications or have experienced psychiatric disturbances, including suicidal events, and most of the drugs have been deregistered for safety reasons."

But the EMA refused to release the clinical trial data for three years, arguing that to do so "would undermine commercial interests."

Commercial interests versus patient welfare

Only after a ruling in June 2010 by the European ombudsman ordering the agency to cough up the information, accusing it of maladministration, did the EMA acquiesce, and it still took the body until February this year to do so.

"The EMA put protecting the profits of the drug companies ahead of protecting the lives and welfare of patients," said the doctors.

The agency's clinical trials database, Eudract, is kept hived off from public scrutiny, despite regular promises to make the information available.

The parliament on Tuesday formally called for a special investigation of conflict of interest at the agency. The chamber at the same time asked for a similar investigation of the European Police College and refused to sign off the accounts for the EU Council of Ministers, although it approved most of the EU's 2009 spending.

After the vote, Green MEP and deputy chair of the parliament's budgetary control committee, Bart Staes, said simply: "The EMA is a mess."

Analysis

A good day for Russia in Europe

Russian firm Gazprom is a reformed character, the European Commission has said, improving the climate for more pipelines to Europe.

New GDPR enforcer says complaints are imminent

The European Data Protection Board is a new EU body tasked with enforcing the EU's privacy laws with powers to impose massive fines. Its head Andrea Jelinek told reporters complaints against companies are expected to be immediate.

Debt relief talks mars Greece's bailout exit

While the Greek government has committed to fulfill the last creditors' requirements in the coming month, Europeans and the International Monetary Fund are still far from an agreement on measures to reduce the country's debt in the future.

Opinion

The dangers of resurgent nationalism in Greece

Virulent nationalism in Greece has been stirred up in the context of austerity and renewed negotiations with Macedonia. Recent attempts by the government to address the inequalities suffered by LGBT persons have also been met with a reactionary backlash.

Stakeholder

Green stadiums at the 2018 FIFA World Cup

By the time the tournament kicks off on 14 June, all twelve stadiums will all have undergone a standards certification process for sustainable buildings.

Debt relief talks mars Greece's bailout exit

While the Greek government has committed to fulfill the last creditors' requirements in the coming month, Europeans and the International Monetary Fund are still far from an agreement on measures to reduce the country's debt in the future.

Analysis

A good day for Russia in Europe

Russian firm Gazprom is a reformed character, the European Commission has said, improving the climate for more pipelines to Europe.

News in Brief

  1. Italy set to pick eurosceptic finance minister
  2. UK foreign minister fooled by Russian pranksters
  3. Rajoy ally gets 33 years in jail for corruption
  4. Close race as polls open in Irish abortion referendum
  5. Gazprom accepts EU conditions on gas supplies
  6. Facebook tells MEPs: non-users are not profiled
  7. Commission proposes ending France deficit procedure
  8. UK households hit with Brexit income loss

Stakeholders' Highlights

  1. Nordic Council of MinistersOECD Report: Gender Equality Boosts GDP Growth in Nordic Region
  2. Centre Maurits Coppieters“Peace and reconciliation is a process that takes decades” Dr. Anthony Soares on #Brexit and Northern Ireland
  3. Mission of China to the EUMEPs Positive on China’s New Measures of Opening Up
  4. Macedonian Human Rights MovementOld White Men are Destroying Macedonia by Romanticizing Greece
  5. Counter BalanceControversial EIB-Backed Project Under Fire at European Parliament
  6. Nordic Council of MinistersIncome Inequality Increasing in Nordic Countries
  7. European Jewish CongressEU Leaders to Cease Contact with Mahmoud Abbas Until He Apologizes for Antisemitic Comments
  8. International Partnership for Human RightsAnnual Report celebrates organization’s tenth anniversary
  9. Nordic Council of MinistersNordic Cooperation Needed on Green Exports and Funding
  10. Mission of China to the EUPremier Li Confirms China Will Continue to Open Up
  11. European Jewish CongressCalls on Brussels University to Revoke Decision to Honour Ken Loach
  12. Sustainable Energy Week 2018"Lead the Clean Energy Transition"- Register and Join Us in Brussels from 5 to 7 May

Stakeholders' Highlights

  1. EU Green Week 2018Green Cities for a Greener Future. Join the Debate in Brussels from 22 to 24 May
  2. Nordic Council of Ministers12 Recommendations for Nordic Leadership on Climate and Environment
  3. Macedonian Human Rights MovementOxford Professor Calls for an End to the Anti-Macedonian Name Negotiations
  4. ACCAPeople Who Speak-Up Should Feel Safe to Do So
  5. Mission of China to the EUProgress on China-EU Cooperation
  6. Nordic Council of MinistersWorld's Energy Ministers to Meet in Oresund in May to Discuss Green Energy
  7. ILGA EuropeParabéns! Portugal Votes to Respect the Rights of Trans and Intersex People
  8. Mission of China to the EUJobs, Energy, Steel: Government Work Report Sets China's Targets
  9. European Jewish CongressKantor Center Annual Report on Antisemitism Worldwide - The Year the Mask Came Off
  10. UNICEFCalls for the Protection of Children in the Gaza Strip
  11. Mission of China to the EUForeign Minister Wang Yi Highlights Importance of China-EU Relations
  12. Nordic Council of MinistersImmigration and Integration in the Nordic Region - Getting the Facts Straight

Stakeholders' Highlights

  1. Macedonian Human Rights MovementMacedonians in Bulgaria Demand to End the Anti-Macedonian Name Negotiations
  2. Counter BalanceThe EIB Needs to Lead by Example on Tax Justice
  3. ILGA EuropeTrans People in Sweden to be Paid Compensation for Forced Sterilisation
  4. International Partnership for Human RightsThe Danger of Standing Up for Justice and Rights in Central Asia
  5. Mission of China to the EUChina and EU Must Work Together to Promote Global Steel Sector
  6. Swedish EnterprisesEU Tax Proposal on Digital Services Causes Concern for Small Exporting Economies
  7. European Jewish CongressCondemns the Horrific Murder of Holocaust Survivor Mireille Knoll in Paris
  8. Mission of China to the EUAn Open China Will Foster a World-Class Business Environment
  9. ECR GroupAn Opportunity to Help Shape a Better Future for Europe
  10. Counter BalanceControversial Turkish Azerbaijani Gas Pipeline Gets Major EU Loan
  11. World VisionSyria’s Children ‘At Risk of Never Fully Recovering', New Study Finds
  12. Macedonian Human Rights MovementMeets with US Congress Member to Denounce Anti-Macedonian Name Negotiations